spacer
home > white papers > Clinical Trials in Russia Orange Paper: 2nd Quarter 2014 - Synergy Research Group
WHITE PAPERS
logo_Synergy_Re.JPG

Synergy Research Group

phone +7 495 600 4445
email request@synrg-pharm.com
web http://www.synrg-pharm.com
email 11, 4-Magistralnaya Ul., 123007 Moscow, Russia

Clinical Trials in Russia Orange Paper: 2nd Quarter 2014

The Ministry of Health of Russian Federation approved 194 new clinical trials of all types including local and bioequivalence studies during the 2nd Quarter of 2014 (3% less than at the same period of the last year).

The main contribution to the total number of studies was made by multinational multi-center clinical trials (MMCT) and the number of these studies stayed the same as in Q2 2013 – 81 studies. The number of bioequivalence studies (BE) decreased from 76 studies in Q2 2013 to 59 in Q2 2014, a 22% decrease from last year’s figure. The number of local clinical trials (LCT) increased from 42 in Q2 2013 to 54 clinical trials in Q2 2014.
Clinical Trials in Russia Orange Paper: 2nd Quarter 2014
spacer

Member login

E-mail address:

Password:
Remember me


News and Press Releases

Charles River Laboratories Makes Investments in High-Throughput Screening Infrastructure

WILMINGTON, Mass.--(BUSINESS WIRE)--Feb. 1, 2018-- Charles River Laboratories International, Inc. (NYSE: CRL) today announced a new agreement which grants Charles River commercial access to AstraZeneca’s (NYSE: AZN) high-throughput screening (HTS) and compound management infrastructure. Through the agreement, Charles River will perform HTS programs for its clients utilizing AstraZeneca’s state-of-the-art HTS facility.
More info >>


White Papers

Life Cycle of an Analytical Method - a Case Study on the Monocyte Activation Test

Wickham Laboratories Limited

Pyrogens, a heterogeneous group of fever inducing contaminants, are comprised of microbial and non-microbial compounds; e.g. endotoxin (lipopolysaccharide, LPS) produced by Gram-negative bacteria, lipoteichoic acid (LTA) from Gram-positive bacteria, bacterial DNA (CpG-motive), endogenous pyrogens, virus and fungi particles or even fragments of packaging materials, plastic and dust. Contaminat ion wi th pyrogens in pharmaceutical products, biotherapeutics and on medical devices can lead to life threatening fever reactions. To ensure consumer safety, pyrogen testing is mandatory for parenteral products and medical devices.
More info >>


Industry Events

Clinical Trial Supply Europe 2018

14-15 March 2018, Milan, Italy

CTS Europe will be returning for the 19th edition next March. This prestigious event will welcome   representatives from 6 of the top 10 pharmaceutical companies in Europe, who will be joined by leading biotech companies across the continent to jointly find solutions for your clinical trial supply problems and discuss changes in the industry.
More info >>


©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement